Patents by Inventor Mattheus Cornelis de Wilde
Mattheus Cornelis de Wilde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150297622Abstract: This invention pertains to the use of an uridine source, preferably uridine monophosphate, for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8 ?M in a subject in need thereof, comprising administering to said subject a composition comprising 300-900 mg of said uridine source daily for a period of at least 4 weeks. In particular, the use of an uridine source is intended forelderly and/or subjects suffering from neurological disorders such as Alzheimer's Disease and dementia syndromes.Type: ApplicationFiled: August 13, 2013Publication date: October 22, 2015Applicant: N.V. NutriciaInventors: Martine GROENENDIJK, Robert Johan Joseph HAGEMAN, Mattheus Cornelis DE WILDE
-
Patent number: 9084804Abstract: Non-medical use of at least two components selected from the group of: (i) nucleoside equivalents, (ii) n-3 polyunsaturated fatty acids selected from the group of DHA, DPA and EPA, (iii) vitamins B, (iv) phospholipids, (v) antioxidants and (vi) cholines—with the proviso that at least one (i) nucleoside or at least one (iii) vitamin B is present—for increasing or maintaining the body weight, for improving the ability to perform an activity of daily living of a mammal, for maintaining the ability to perform an activity of daily living of a mammal, or for reducing a deterioration in the ability to perform an activity of daily living of a mammal.Type: GrantFiled: August 11, 2011Date of Patent: July 21, 2015Assignee: N.V. NutriciaInventors: Martine Groenendijk, Patrick Joseph Gerardus Hendrikus Kamphuis, Mattheus Cornelis De Wilde, Robert Johan Joseph Hageman
-
Publication number: 20150044138Abstract: The invention relates to a composition comprising: (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, for use in preserving or improving functional synaptic connectivity and/or preserving brain network organization in a subject in need thereof.Type: ApplicationFiled: March 4, 2013Publication date: February 12, 2015Applicant: N.V. NutriciaInventors: Marieke Lansbergen, Martine Groenendijk, Patrick Joseph Gerardus Hendrikus Kamphuis, Mattheus Cornelis De Wilde
-
Patent number: 8791089Abstract: The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its equivalent. The operational activities comprise eating; walking; toileting; bathing; grooming; dressing; use of communication equipment; making conversations; keeping appointments; use of household appliances; cleaning dishes; preparation of meal or drink; writing; reading; independent housekeeping; transportation and shopping.Type: GrantFiled: January 18, 2013Date of Patent: July 29, 2014Assignee: N.V. NutriciaInventors: Martine Groenendijk, Mattheus Cornelis de Wilde, Robert Johan Joseph Hageman, Patrick Joseph Gerardus Hendrikus Kamphuis
-
Publication number: 20140066397Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.Type: ApplicationFiled: March 14, 2012Publication date: March 6, 2014Inventors: Mattheus Cornelis De Wilde, Johannes Wilhelmus Christina Suben, Patrick Joseph Gerardus Hendrikus Kamphuis, Robert Johan Joseph Hageman
-
Publication number: 20130331352Abstract: Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ?-3 polyunsaturated fatty acid selected from the group of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant and (vi) a choline, with the proviso that at least component (i) or (iii) is present, for use in the prevention or treatment of frailty in a mammal, wherein frailty is determined by compliance with at least 2 criterions, preferably 3 criterions, selected from the group of muscle weakness, excessive feelings of exhaustion or fatigue, abnormally low physical activity, slow or unsteady gait, weight loss, and neurological dysfunction.Type: ApplicationFiled: December 28, 2011Publication date: December 12, 2013Applicant: N.V. NUTRICIAInventors: Robert Johan Joseph Hageman, Mattheus Cornelis De Wilde, Martine Groenendijk, Patrick Joseph Gerardus Hendrikus Kamphuis
-
Publication number: 20130330424Abstract: Non-medical use of at least two components selected from the group of: (i) nucleoside equivalents, (ii) n-3 polyunsaturated fatty acids selected from the group of DHA, DPA and EPA, (iii) vitamins B, (iv) phospholipids, (v) antioxidants and (vi) cholines—with the proviso that at least one (i) nucleoside or at least one (iii) vitamin B is present—for increasing or maintaining the body weight, for improving the ability to perform an activity of daily living of a mammal, for maintaining the ability to perform an activity of daily living of a mammal, or for reducing a deterioration in the ability to perform an activity of daily living of a mammal.Type: ApplicationFiled: August 11, 2011Publication date: December 12, 2013Applicant: N.V. NutriciaInventors: Martine Groenendijk, Patrick Joseph Gerardus Hendrikus Kamphuis, Mattheus Cornelis De Wilde, Robert Johan Joseph Hageman
-
Publication number: 20130295146Abstract: It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises: a) a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.Type: ApplicationFiled: July 2, 2013Publication date: November 7, 2013Applicant: N.V. NUTRICIAInventors: Robert Johan Joseph HAGEMAN, Mattheus Cornelis DE WILDE, Patrick Joseph Gerardus Hendrikus KAMPHUIS
-
Patent number: 8497238Abstract: It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises: a) a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.Type: GrantFiled: June 20, 2008Date of Patent: July 30, 2013Assignee: N.V. NutriciaInventors: Robert Johan Joseph Hageman, Mattheus Cornelis De Wilde, Patrick Joseph Gerardus Hendrikus Kamphuis
-
Patent number: 8361989Abstract: The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its equivalent. The operational activities comprise eating; walking; toileting; bathing; grooming; dressing; use of communication equipment; making conversations; keeping appointments; use of household appliances; cleaning dishes; preparation of meal or drink; writing; reading; independent housekeeping; transportation and shopping.Type: GrantFiled: June 20, 2008Date of Patent: January 29, 2013Assignee: N. V. NutriciaInventors: Martine Groenendijk, Mattheus Cornelis de Wilde, Robert Johan Joseph Hageman, Patrick Joseph Gerardus Hendrikus Kamphuis
-
Publication number: 20120165412Abstract: The present invention relates to the use of an hydroxylated stilbene, in particular resveratrol, in the manufacture of a neutraceutical composition for increasing the microvascular plasticity and/or microvessel density, and/or decreasing the microvessel abnormalities in the brain, in particular in the hippocampus of a mammal, in particular for the treatment of age- and condition-related decline in brain neuronal function and/or cognitive functioning in a mammal. In particular, the condition is selected from the group of Alzheimer's Disease, dementia, depression, sleep disorders, impaired memory function, psychoses, Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, ADHD and anxiety.Type: ApplicationFiled: February 19, 2010Publication date: June 28, 2012Applicant: N.V. NutriciaInventors: Eline Marleen van der Beek, Mattheus Cornelis de Wilde, Martine Groenendijk, Patrick Joseph Gerardus Hendrikus Kamphuis
-
Publication number: 20100331275Abstract: The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its equivalent. The operational activities comprise eating; walking; toileting; bathing; grooming; dressing; u se of communication equipment; making conversations; keeping appointments; use of household appliances; cleaning dishes; preparation of meal or drink; writing; reading; independent housekeeping; transportation and shopping.Type: ApplicationFiled: June 20, 2008Publication date: December 30, 2010Inventors: Martine Groenendijk, Mattheus Cornelis De Wilde, Robert Johan Joseph Hageman, Patrick Joseph Gerardus Hendrikus Kamphuis
-
Publication number: 20080317868Abstract: It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises: a) a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.Type: ApplicationFiled: June 20, 2008Publication date: December 25, 2008Applicant: N.V. NUTRICIAInventors: Robert Johan Joseph Hageman, Mattheus Cornelis De Wilde, Patrick Joseph Gerardus Hendrikus Kamphuis